PCM
NXTM

Portolan Capital Management’s NxStage Medical Inc. NXTM Stock Holding History

Portolan Capital Management’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-492,188
Closed -$12.3M – 136
2017
Q2 		$12.3M Sell
492,188
-52,844
-10% -$1.31M 1.58% 17
2017
Q1 		$14.6M Sell
545,032
-31,231
-5% -$863K 1.9% 9
2016
Q4 		$15.1M Buy
576,263
+44,021
+8% +$1.09M 2.03% 5
2016
Q3 		$13.3M Buy
532,242
+316,432
+147% +$7.38M 1.83% 10
2016
Q2 		$4.68M Buy
+215,810
New +$3.85M 0.67% 60

Other funds holding NXTM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Portolan Capital Management's NXTM Position: Q3 2017 in Review

Portolan Capital Management sold out of NxStage Medical Inc. (NXTM) in Q3 2017, closing a stake of 492,188 shares — an estimated $12.3M sold.

Portolan Capital Management first reported a position in NXTM in Q2 2016 and held it in 5 quarters. The position peaked at $15.1M in Q4 2016. 168 funds tracked by Wall St. Rank hold NXTM as of Q3 2017.

  • Portolan Capital Management reported no remaining NxStage Medical Inc. position as of Q3 2017 after selling out during the quarter.
  • Portolan Capital Management sold 492,188 NxStage Medical Inc. shares in Q3 2017, an estimated $12.3M.
  • Portolan Capital Management first reported a position in NxStage Medical Inc. in Q2 2016 and held it in 5 quarters.
  • Portolan Capital Management's NxStage Medical Inc. position peaked at $15.1M in Q4 2016.
  • 168 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q3 2017.

Based on Portolan Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.